MPR

🗣️ New Weekly Dose Pod out now! ⚖️ Court blocks HHS changes to immunization schedule; 💉 Higher dose Wegovy approved; 🧒 Cosentyx for pediatric hidradenitis suppurativa; and 🔸 Investigational Tx shows significant weight reduction in diabetes. empr.com/news/mpr-weekl…

The treatment is now approved for weight management in adults and children with acquired hypothalamic #obesity. empr.com/news/fda-appro…

The weight loss treatment Wegovy now has a high-dose option. empr.com/news/high-dose…

Talazoparib treatment regimen demonstrated a significant improvement in radiological progression free survival vs placebo plus enzalutamide. empr.com/news/talazopar…

The judge has suspended all votes by RFK Jr's restructured CDC vaccine panel, ruling that recent appointments likely violate the Federal Advisory Committee Act. empr.com/news/court-blo…

Law feature: A patient harmed by their own noncompliance may still file for medical malpractice. This month's feature looks at one such case. empr.com/features/famil…

Ebglyss shows positive results for pediatric patients with atopic #dermatitis. # empr.com/news/lebrikizu…

Patients were randomly assigned 1:1 to receive bimekizumab or risankizumab. The endpoint was the proportion of patients achieving at least a 50% improvement from baseline in ACR response. empr.com/news/bimekizum…

An independent monitoring committee concluded that the study was unlikely to meet its primary endpoints. empr.com/news/phase-3-n…

📢 Don't miss this week's Weekly Dose podcast to get caught up on some important FDA approvals, including the controversial leucovorin. empr.com/news/mpr-weekl…

Leucovorin approved for rare neuro disorder. Agency officials met backlash last year when they suggested leucovorin may be a treatment option for autism. empr.com/news/leucovori…

Adults aged 18 to 49 years at increased risk for RSV-associated lower respiratory tract disease are now eligible for the Arexvy #vaccine. empr.com/news/arexvy-ap…

📣 New MPR Pod out now! This week: 🔹Sotyktu approval expanded; 🔸Leucovorin approved for rare disorder, not autism; 🔹Tazverik withdrawn from market; and 🔸FDA to review potential new hypertension Tx. empr.com/news/mpr-weekl…

The Trump White House views vaping as an election issue. Last year the admin banned most flavored vaping products. empr.com/news/fda-may-a…

The virus has been detected in several parts of the world during the past year, including the United Kingdom and Germany. empr.com/news/going-abr…

Bimekizumab demonstrated superiority over risankizumab in achieving at least a 50% improvement in symptoms of psoriatic arthritis in the trial. empr.com/news/bimekizum…

Last year FDA Commissioner Marty Makary said the Agency was aiming to broaden the labeling for leucovorin for CFD, linking the medication as a potential treatment for autism. empr.com/news/leucovori…

From January 2016 to June 2024, there was an increase from 0.16 to 0.44 per 1000 people for stimulant dispensations. empr.com/news/rapid-acc…

In April the FDA is expected to decide on treatments for Alzheimer disease agitation, focal segmental glomerulosclerosis, hematological malignancies, HIV-1, and obesity. empr.com/news/fda-drug-…

Trial results showed lorundrostat 50mg significantly reduced SBP compared with placebo at week 6, with a placebo adjusted reduction of -9.1mmHg. empr.com/news/fda-grant…